---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-036263"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T16:10:15.612968+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics appoints Matthew Klein as CEO; founder Stuart Peltz retires

## Summary
- Stuart Peltz retires after 25 years as CEO; Matthew Klein appointed CEO and President, effective March 22, 2023.
- Peltz will serve as Senior Advisor & join Scientific Advisory Board; consulting fee of $600k for first 12 months, then $400k.
- Klein had been COO since Jan 2022; previously Global Head of Gene & Mitochondrial Therapies and Chief Development Officer.
- Peltz receives prorated 2023 annual bonus equal to 25% of his 2022 bonus; unvested equity continues vesting during consulting period.
- PTC's broad pipeline includes five registration-directed trials; Klein led EMA approval of Upstaza gene therapy.

## SEC filing metadata
- accession: 0001104659-23-036263
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/0001104659-23-036263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/tm2310367d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-036263
- JSON: https://secwatch.observer/filing/0001104659-23-036263.json
- Plain text: https://secwatch.observer/filing/0001104659-23-036263.txt

## Key facts
- Executive change
  Stuart W. Peltz retired as Chief Executive Officer at PTC THERAPEUTICS, INC..
  - Action: retired
  - Role: Chief Executive Officer
  source text: Dr. Stuart W. Peltz, who provided the Board with notice on March 22, 2023 of his decision to retire as Chief Executive Officer and as a member of the Board, in each case, effective as of March 22, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/0001104659-23-036263-index.htm
- Executive change
  Matthew B. Klein was appointed as Chief Executive Officer and President at PTC THERAPEUTICS, INC..
  - Action: appointed
  - Role: Chief Executive Officer and President
  source text: the Board of Directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”) appointed Dr. Matthew B. Klein, age 51, as Chief Executive Officer and President and a member of the Board, effective as of March 22, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/0001104659-23-036263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.